Investment firm Anterra Capital led a $15m Series A round in Invetx, a pioneering animal health biopharmaceutical company. "Invetx was created to translate the biotechnology revolution that has transformed human medicine to the world of animal health. We have built a foundational network of first-in-class global partners to deliver that translation and develop a sustainable platform for veterinary biopharmaceutical innovation," Juergen Horn, Invetx CEO.